Kongreßbeiträge

Rühl M, Atkinson J, **Johannsen M**, Manski D, Sahin E, Schuppan D. Collagen VI regulates normal and transformed mesenchymal cell proliferation in vitro via protein kinase pathways. 2nd International Dahlem Symposium on Cellular Signal Recognition and Transduction, Berlin, Oct. 1996

Rühl M, **Johannsen M**, Manski D, Atkinson J, Sahin E, Schuppan D. Collagen VI is a growth promoting agent. 3rd International Colloquium on Cellular Signal Recognition and Transduction, Berlin, Oct. 1997

Rühl M, Sahin E, **Johannsen M**, Riecken E O, Schuppan D. Collagen VI is an anti-apoptotic agent. 3rd International Colloquium on Cellular Signal Recognition and Transduction, Berlin, Oct. 1997

Rühl M, **Johannsen M**, Manski D, Atkinson J, Sahin E, Schuppan D. Soluble collagen type VI induces tyrosine-phosphorylation of Paxillin and Focal Adhesion Kinase and activates the MAP-Kinase Erk2 in fibroblasts. 4th International Dahlem Symposium on Cellular Signal Recognition and Transduction, Oct.1998

Rühl M, Sahin E, **Johannsen M**, Riecken E O, Schuppan D. Soluble collagen VI drives serum-starved fibroblasts through S-phase and prevents apoptosis via downregulation of BAX. 4th International Dahlem Symposium on Cellular Signal Recognition and Transduction, Oct.1998
Johannsen M, Wille A, Roigas J, Schnorr D. Combination Therapy with Taxol and Carboplatin in Advanced Transitional Cell Cancer. Annual meeting European Association of Urology, Eur Urol 2001; 39 (Suppl 5): 141

Miller K, Steiner U, Machtens S, Backhaus B, Siegsmund M, **Johannsen M**, Wülfing C. Phase II study of combination chemotherapy with weekly docetaxel and intermittent estramustine in patients with symptomastic hormone-refractory prostate cancer (HRPC). Annual meeting American Society of Clinical Oncology, J Clin Oncol 2002; (Suppl); ASCO #2448

Miller K, Steiner U, Machtens S, Backhaus B, Siegsmund M, **Johannsen M**, Wülfing C. Combination chemotherapy with weekly docetaxel and intermittent estramustine in patients with symptomatic hormone-refractory prostate cancer (HRCP): A multicenter phase II study. Annual meeting American Society of Clinical Oncology, J Clin Oncol 2003; (Suppl) ASCO # 1660

Johannsen M, Jordan A, Scholz R, Lein M, Koch M, Deger S, Roigas J, Jung K, Loening SA. In vivo-effects of Magnetic Fluid Hyperthermia (MFH) in a prostate cancer standard rat model. European Society of Hyperthermic Oncology meeting 2003, 04.-07.06.03, München

Wille A, **Johannsen M**, Daniltchenko D, Roigas J, Schnorr D. Taxol and Carboplatin in the treatment of advanced or metastatic cancer of the bladder. The VIth Russian Oncourological Conference, 2.10.-3.10.2003, Obninsk, Russia

Wille A, **Johannsen M**, Roigas J, Schnorr D. Phase II trial of Paclitaxel and Carboplatin in advanced / metastatic transitional cell cancer. Annual meeting American Urological Association, J Urol 2003; 169, No.4 (Suppl): 380/81

Johannsen M, Jordan A, Scholz R, Lein M, Koch M, Deger S, Roigas J, Jung K, Loening SA. Evaluation of Magnetic Fluid Hyperthermia (MFH) in a prostate cancer standard rat model. Annual meeting American Urological Association, J Urol 2003; 169, No.4 (Suppl): 218

Urologische Facharztpraxis
PD Dr. Johannsen

Priv. Doz.
Dr. med. Manfred Johannsen
(F.E.B.U.)

Facharzt für Urologie
und Andrologie
Medikamentöse Tumortherapie

Carl-Schurz-Str. 31
13597 Berlin
Tel. 030 333 40 30
Fax 030 333 17 83

www.urologie-in-spandau.de
info@urologie-in-spandau.de

Roigas J, Deger S, Wille A, **Johannsen M**, Türk I, Loening S. Response and survival following chemoimmunotherapy for metastatic renal cell carcinoma in 107 consecutive patients – results of a retrospective single center analysis. Annual meeting European Association of Urology, Eur Urol 2003; 1 (Suppl 2): 98

Wille AH, **Johannsen M**, Roigas J, Schnorr D. Therapie des fortgeschrittenen Urothelkarzinoms mit Taxol und Carboplatin..Jahreskongreß der Deutschen Gesellschaft für Urologie, Hamburg, 26.9. 2003

Johannsen M, Wille AH, Roigas J, Schnorr D, Loening SA. Phase II trial of paclitaxel and carboplatin in advanced / metastatic transitional cell cancer. Annual meeting European Association of Urology, Vienna, 25.03.2004

Johannsen M, Wille AH, Roigas J, Schnorr D, Loening SA. Phase II trial of paclitaxel and carboplatin in advanced / metastatic transitional cell cancer. Annual meeting European Association of Urology, Vienna, Eur Urol 2004; 3 (Suppl 2): 177

Johannsen M, Thiesen B, Taymoorian K, Gneveckow U, Waldöfner N, Koch M, Scholz R, Lein M, Jung K, Loening SA. Evaluation of magnetic fluid hyperthermia (MFH) combined with external radiation in an orthotopic rat model of prostate cancer. Jahreskongreß der Deutschen Gesellschaft für Urologie, Wiesbaden, 24.09.2004

Johannsen M, Thiesen B, Taymoorian K, Gneveckow U, Waldöfner N, Koch M, Scholz R, Lein M, Jung K, Loening SA, Jordan A. Evaluation of magnetic fluid hyperthermia (MFH) combined with external radiation in an orthotopic rat model of prostate cancer. Annual meeting European Association of Urology, Eur Urol 2005; 3 (Suppl 4): 54

Miller K, Wülfing C, Lehmann J, **Johannsen M**, Heidenreich A, Hegele A, Backhaus B, Steiner U. Weekly docetaxel plus estramustine for hormone-refractory prostate cancer (HRPC) with intermittent repetition: Preliminary results of a multicenter Phase II study (AUO AP33/02). Annual meeting American Society of Clinical Oncology, J Clin Oncol 2005; (Suppl); ASCO #4613

Johannsen M, Gneveckow U, Wust P, Taymoorian K, Thiesen B, Waldöfner N, Deger S, Scholz R, Feussner A, Loening SA, Jordan A. Thermotherapy using magnetic nanoparticles in patients with locally recurrent prostate cancer: initial results of a phase I study. Annual meeting European Association of Urology, Eur Urol 2006; 5 (Suppl 2): 131

Johannsen M, Gneveckow U, Thiesen B, Feussner A, Waldöfner N, Scholz R, Jordan A, Loening SA, Wust P. Thermotherapie des Prostatakarzinoms mittels magnetischer Nanopartikel: Ergebnisse einer Phase I Studie. Jahreskongreß der Deutschen Gesellschaft für Urologie, Hamburg, 21.9. 2006

Johannsen M, Roemer A, Spitaleri G, Curigliano G, Giovannoni L, Menssen HD, Zardi L, Neri D, Miller K, de Braud FG. Phase I/II study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in patients with advanced renal cell carcinoma. Annual meeting American Society of Clinical Oncology, J Clin Oncol 26: 2008 (May 20 suppl; abstr 16032)

Johannsen M, Kempkensteffen C, Miller K, Weikert S. Therapie des fortgeschrittenen Nierenzellkarzinoms nach einer Tyrosinkinase-Inhibitor-Therapie: Erste Erfahrungen mit Everolimus (Afinitor®) in der Praxis. Onkologie 2010;33(suppl 2):90

Urologische Facharztpraxis
PD Dr. Johannsen

Priv. Doz.
Dr. med. Manfred Johannsen
(F.E.B.U.)

Facharzt für Urologie
und Andrologie
Medikamentöse Tumortherapie

Carl-Schurz-Str. 31
13597 Berlin
Tel. 030 333 40 30
Fax 030 333 17 83

www.urologie-in-spandau.de
info@urologie-in-spandau.de